Detalhe da pesquisa
1.
Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
BMC Cancer
; 24(1): 146, 2024 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38287346
2.
Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
Eur J Nucl Med Mol Imaging
; 50(4): 1195-1204, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454268
3.
Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients.
Eur J Nucl Med Mol Imaging
; 49(9): 3203-3214, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35230492
4.
Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
J Urol
; 205(4): 1100-1109, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207138
5.
False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC).
J Surg Oncol
; 124(7): 1161-1165, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34235758
6.
Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours.
EJC Suppl
; 16: 5-13, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34912478
7.
Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
BJU Int
; 125(2): 206-214, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31680398
8.
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
BMC Cancer
; 19(1): 325, 2019 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30953466
9.
Reply by Authors.
J Urol
; 205(4): 1108-1109, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33493004
10.
Radionuclide therapy in the time of COVID-19.
Eur J Nucl Med Mol Imaging
; 47(9): 2066-2067, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32548661
11.
How to design a theranostic trial?
Endocr Oncol
; 4(1): e230045, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38770190
12.
Reduction of [68Ga]Ga-DOTA-TATE injected activity for digital PET/MR in comparison with analogue PET/CT.
EJNMMI Phys
; 11(1): 27, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38488989
13.
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.
EJNMMI Radiopharm Chem
; 9(1): 9, 2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319526
14.
Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients.
J Nucl Med
; 64(1): 40-46, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35680417
15.
68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer.
J Nucl Med
; 64(10): 1556-1562, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37536738
16.
Peptide Receptor Radionuclide Therapy.
J Clin Endocrinol Metab
; 107(12): 3199-3208, 2022 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36198028
17.
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients.
Cancers (Basel)
; 14(23)2022 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36497273
18.
Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
Pharmaceutics
; 14(10)2022 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36297601
19.
Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patients.
Eur J Endocrinol
; 187(1): 209-217, 2022 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35560282
20.
Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men.
Clin Nucl Med
; 47(7): 599-605, 2022 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35426841